Navigation Links
Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
Date:5/25/2010

BASKING RIDGE, N.J., May 25 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, today announced issuance of another key patent related to their proprietary technology.  This new patent includes coverage for RB007, the modulator or active control component of Regado's innovative product candidates, the REG1 and REG2 anticoagulation systems.  The allowed claims in U.S. Patent No. 7,723,315 broadly cover modulators that are capable of binding to certain blood coagulation Factor IX/IXa inhibiting aptamers and include both composition of matter and methods of use claims.  The term for this patent extends to April 2025.

ABOUT REGADO BIOSCIENCES

Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems.  Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent.  This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care setting, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control.  Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.

ABOUT REG1 and REG2  

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Regado Biosciences REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
2. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
3. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
4. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
5. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
6. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
7. Regado Biosciences Establishes Medical Advisory Board
8. Regado Biosciences Expands Medical Advisory Board
9. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
10. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
11. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... -- Senomyx , Inc. (NASDAQ: SNMX ... discover, develop, and commercialize novel flavor ingredients, announced today ... Company,s Vice President, Biology and Gwen Rosenberg ... will present an overview of Senomyx,s technology and programs ... (7:25 a.m. Pacific Time) during the Citi 2013 Global ...
(Date:5/24/2013)... Canada (PRWEB) May 24, 2013 Many ... barriers, and uptake or efflux transporters at the blood-tissue ... be related to unbound fractions in the tissue rather ... of these disposition challenges is required to guide lead ... to identify any species-dependent variables that may impact the ...
(Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") a ... research and development, sales and marketing of premium ... today that it is awarding exclusive Vestiage territories ... Reluma Skin Illuminating Facial Care. Qualified applicants can ... an email to info(at)vestiageinc(dot)com and putting RELUMA in ...
(Date:5/23/2013)... Die Übersetzungen wurden von PRNewswire ... der englischen Version handelt es sich um ... Teilnehmer einer groß angelegten Asthmaumfrage halten ihren Zustand für ... -Definition [1] als kontrolliert gelten können ... von vier Denkweisen zugeordnet werden können, die alle von ...
Breaking Biology Technology:SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7
... , , , ... that Professor Nancy Ip, Chair Professor of the Department of ... Kong University of Science and Technology (HKUST), has joined their ... Academy of Sciences and recipient of China,s highest honor in ...
... 17 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... company focused on endocrine therapy and oncology, today reported ... Z-033 and the safety trial Z-041 in benign prostatic ... cetrorelix pamoate. As announced on March 6, 2009, sanofi-aventis ...
... all containers at international ports could be the most ... transportation system are not carrying nuclear bombs, according to ... group meeting of the Institute for Operations Research and ... federal scheme now in place that relies on targeting ...
Cached Biology Technology:Professor Nancy Ip Joins aTyr Pharma's Scientific Advisory Board 2AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 3AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 4AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 5AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 6AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 7Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 2Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 3Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 4
(Date:5/23/2013)... In an age when microbial pathogens are growing increasingly ... infection, a team of Wisconsin scientists has synthesized a ... bacteria that cause staph infections. , Writing online in ... a group led by University of Wisconsin-Madison chemistry Professor ... "quorum sensing" behavior of Staphylococcus aureus , a ...
(Date:5/22/2013)... physicists have developed a novel technique that can detect ... process that is one of the most important, though ... in a paper in Nature , post-doctoral researcher ... Melanie Schnell of the Center for Free-Electron Laser Science ... on finely-tuned microwave fields to identify molecular variants apart, ...
(Date:5/22/2013)... potential environmental and human health effects from disposal ... has led scientists to recommend stronger government policies ... (Li-ion) battery materials. That,s the conclusion of a ... Science & Technology . , Oladele A. Ogunseitan ... become mainstays for powering everything from smart phones ...
Breaking Biology News(10 mins):University of Wisconsin chemists find new compounds to curb staph infection 2Detecting mirror molecules 2Detecting mirror molecules 3
... a small biotech company in Boulder, CO, announced today that ... Colorado. The FluChip was invented by a joint team ... for Disease Control and Prevention in an NIH sponsored effort ... the CEO of InDevR, said that InDevR has arranged to ...
... , The Entomological Society of America (ESA) will ... Annual Meeting in Indianapolis, December 13-16, 2009. ... Cold Case Files: Integrative Perspectives on ... Temperature Evolutionary Arms Race of Resistance in ...
... beneficial arrangements between organismslike the relationship between flowering ... blissful relationships have a dark side, as Harvard ... the May issue of The American Naturalist ... plants is a great example of biological mutualism. ...
Cached Biology News:FluChip technology licensed to combat deadly flu virus 2Symposia selected for Entomological Society of America meeting 2Symposia selected for Entomological Society of America meeting 3Symposia selected for Entomological Society of America meeting 4When industrious ants go too far 2
The Captivate Disposable Sample Chamber is designed for use with the Captivate magnetic yoke assembly (C-24700) and can be used with our Captivate ferrofluid conjugates (C-21473 C-21474 C-21476) or ...
MOUSE ANTI HUMAN MOC31:AZIDE FREE...
... mycobacteria in Complete Freund's adjuvant attract macrophages ... which enhances the immuneresponse. For this reason, ... the initial injections; Incomplete Freund's adjuvant is ... in saline) are typically mixed with an ...
HiTrap Streptavidin HP, 5 x 1 ml. Category: Chromatography Systems & Accessories, Systems....
Biology Products: